TP53 and Miyoshi myopathy: Routine assessment of TP53 mutational status in MM is particularly crucial for patients with multi-hit TP53 and those with TP53mut but without del(17p), as they will not be correctly risk stratified and are thus less likely to be prioritised for novel therapies within trials or for earlier or optimised therapeutic intervention (Berdeja et al. 2021; Moreau et al. 2022; Munshi et al. 2021; Pasvolsky et al. 2023).